-Resistance of isolated microorganisms to the tested antimicrobial drugs.
Antimicrobial drugs Isolated microorganisms

Pseudomonas aeruginosa
Acinetobacter spp.
Klebsiella pneumoniae Stenotrophomonas maltophilia
Enterobacter spp. Amikacin  63  47  40  60  59  41  9  91  80  20  Amoxicillin and clavulanic acid  0  100  4  96  8  92  0  100  0  100  Ampicillin  0  100  0  100  0  100  0  100  0  100  Cefalexin  0  100  6  94  0  100  0  100  0  100  Cefepime  59  41  0  100  14  86  36  64  40  60  Ceftazidime  78  22  0  100  14  86  55  45  50  50  Ceftriaxone  13  87  --16  84  0  100  40  60  Ciprofloxacin  53  47  12  88  43  57  82  18  80  20  Gentamycin  50  50  10  90  59  41  49  51  70  30  Imipenem  59  41  4  96  100  0  0  100  100  0  Meropenem  75  25  44  56  100  0  0  100  100  0  Tazocin (piperacillin+ tazobactam)  78  22  4  96  78  22  45  55  100  0  Tigecycline  0  100  4  96  0  100  0  100  0  100  Trimethoprim sulfamethoxazole  3  97  0  100  19  81  73  27  80 patients with suspected VAP, 29% had no bacteria, 28% had only one isolated bacteria, while the remaining 43% of patients had polymicrobial isolates.
Testing bacterial sensitivity to antimicrobial drugs was performed using a standard disc diffusion method by KirbyBauer, according to the guidelines of the European Committee. All isolated microorganisms showed over 50% resistance for amoxicillin + clavulanic acid, ampicillin, cefalexin, ceftriaxone, and tigecyclin (Table 1) .
Acinetobacter spp. was the most prevalent bacteria (65%) in respiratory secretion of patients on MV, and it presented multidrug-resistance in over 90% of cases. Results from this research showed identification of polymicrobial isolates in 43% of cases; 23% of cases presented two bacteria, 16% presented three bacteria, 3% presented four bacteria, and 1% presented five bacteria. Combes et al., 4 isolated two bacteria in 70% of cases; however, they found 16.7% of tribacterial cases, similarly to our findings.
In our research, Klebsiella pneumoniae was resistant to thirdgeneration cephalosporins in over 80% of cases, while in a study from Poland the resistance rate ranged from 56% to 73%. 5 The mortality rate was 68%, which is in agreement with the literature. 1,2 Based on the data obtained, we can conclude that the incidence of VAP at the ICU was high.
